Cigna gets outcomes-based discounts for PCSK9s

Cigna Corp. (NYSE:CI) said Wednesday that it signed outcomes-based pricing contracts covering cholesterol-lowering PCSK9 drugs Praluent alirocumab and Repatha evolocumab. Cigna said the contracts include a negotiated price, provided

Read the full 291 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE